Strategic partnerships Private, profitably funded European-focused distributor with offices across Ireland, UK, and Nordics, actively expanding Benelux and Spain. Opportunity: collaborate on in-licensing late-stage developments or marketed products to accelerate geographic footprint and portfolio growth.

Portfolio acceleration Specializes in women’s health, urology and endocrinology with a services model spanning regulatory, market access, supply chain, medical affairs, marketing and sales. Opportunity: partner on commercialization rights, leverage their market access capabilities to bring in accelerated value for partners’ brands.

Non-R&D model Does not conduct R&D or manufacturing; focuses on commercialization, regulatory affairs and distribution. Opportunity: approach for licensing mature assets or in-licensing opportunities where Consilient Health can de-risk go-to-market and scale quickly without product development burden.

Recent launches Executed launches such as Ghryvelin for Growth Hormone Deficiency and Cytisine 1.5mg in the UK, with a track record of market entry and regulatory navigation. Opportunity: identify late-stage or marketed product opportunities in Europe that align with their therapeutic focus to exploit their launch capabilities.

Financially agile Privately-held, profitable with a strong balance sheet and revenue in the low single digits, enabling quick decision-making and long-term collaborations. Opportunity: propose strategic partnerships, co-promotion, or exclusive distribution rights that require flexible capital deployment and faster timeline.